Literature DB >> 18289193

Ten common statistical errors and how to avoid them.

Alan R Zinsmeister, Jason T Connor.   

Abstract

Mesh：

Year:  2008        PMID： 18289193     DOI： 10.1111/j.1572-0241.2007.01590.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN： 0002-9270            Impact factor:   10.864


× No keyword cloud information.
  10 in total

1.  No impact of perioperative blood transfusion on recurrence of hepatocellular carcinoma after hepatectomy.

Authors:  Shintaro Kuroda; Hirotaka Tashiro; Tsuyoshi Kobayashi; Akihiko Oshita; Hironobu Amano; Hideki Ohdan
Journal:  World J Surg       Date:  2012-03       Impact factor: 3.352

2.  Clinicopathological features of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease.

Authors:  Yoshihiro Mikuriya; Hirotaka Tashiro; Tsuyoshi Kobayashi; Shintaro Kuroda; Tomoyuki Abe; Masakazu Hashimoto; Hideki Ohdan
Journal:  Langenbecks Arch Surg       Date:  2015-03-06       Impact factor: 3.445

3.  Safety of hepatic resection for colorectal metastases in the era of neo-adjuvant chemotherapy.

Authors:  Alessandro Cucchetti; Giorgio Ercolani; Matteo Cescon; Paolo Di Gioia; Eugenia Peri; Giovanni Brandi; Sara Pellegrini; Antonio Daniele Pinna
Journal:  Langenbecks Arch Surg       Date:  2011-12-24       Impact factor: 3.445

4.  Thrombopoietin Receptor Agonists Are Often Ineffective in Immune Thrombocytopenia and/or Cause Adverse Reactions: Results from One Hand.

Authors:  Fabian Depré; Nasra Aboud; Frauke Ringel; Abdulgabar Salama
Journal:  Transfus Med Hemother       Date:  2016-07-18       Impact factor: 3.747

5.  Biostatistics: a toolkit for exploration, validation, and interpretation of clinical data.

Authors:  Jayawant N Mandrekar; Sumithra J Mandrekar
Journal:  J Thorac Oncol       Date:  2009-12       Impact factor: 15.609

6.  Laparoscopic Liver Resection versus Percutaneous Radiofrequency Ablation for Small Single Nodular Hepatocellular Carcinoma: Comparison of Treatment Outcomes.

Authors:  Dong Ho Lee; Jing Woong Kim; Jeong Min Lee; Jong Man Kim; Min Woo Lee; Hyunchul Rhim; Young Hoe Hur; Kyung-Suk Suh
Journal:  Liver Cancer       Date:  2021-01-14       Impact factor: 11.740

7.  ITPA polymorphism effects on decrease of hemoglobin during sofosbuvir and ribavirin combination treatment for chronic hepatitis C.

Authors:  Kei Morio; Michio Imamura; Yoshiiku Kawakami; Takashi Nakahara; Yuko Nagaoki; Tomokazu Kawaoka; Masataka Tsuge; Akira Hiramatsu; Hiroshi Aikata; Clair Nelson Hayes; Grace Naswa Makokha; Hidenori Ochi; Hajime Amano; Keiko Arataki; Takashi Moriya; Hiroyuki Ito; Keiji Tsuji; Hiroshi Kohno; Koji Waki; Toru Tamura; Toshio Nakamura; Kazuaki Chayama
Journal:  J Gastroenterol       Date:  2016-11-07       Impact factor: 6.772

8.  Systematic survey of the design, statistical analysis, and reporting of studies published in the 2008 volume of the Journal of Cerebral Blood Flow and Metabolism.

Authors:  Hanna M Vesterinen; Hanna V Vesterinen; Kieren Egan; Amelie Deister; Peter Schlattmann; Malcolm R Macleod; Ulrich Dirnagl
Journal:  J Cereb Blood Flow Metab       Date:  2010-12-15       Impact factor: 6.200

9.  The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy.

Authors:  Yuko Nagaoki; Michio Imamura; Hiroshi Aikata; Kana Daijo; Yuji Teraoka; Fumi Honda; Yuki Nakamura; Masahiro Hatooka; Reona Morio; Kei Morio; Hiromi Kan; Hatsue Fujino; Tomoki Kobayashi; Keiichi Masaki; Atsushi Ono; Takashi Nakahara; Tomokazu Kawaoka; Masataka Tsuge; Akira Hiramatsu; Yoshiiku Kawakami; C Nelson Hayes; Daiki Miki; Hidenori Ochi; Kazuaki Chayama
Journal:  PLoS One       Date:  2017-08-10       Impact factor: 3.240

10.  Ginsenoside-Rb1 for Ischemic Stroke: A Systematic Review and Meta-analysis of Preclinical Evidence and Possible Mechanisms.

Authors:  Yi-Hua Shi; Yan Li; Yong Wang; Zhen Xu; Huan Fu; Guo-Qing Zheng
Journal:  Front Pharmacol       Date:  2020-03-31       Impact factor: 5.810
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.